title: Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: report of a retrospective case study.
abstract: OBJECTIVE
  The purpose of this study was to study the use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography (F-18 FDG PET) for monitoring therapeutic response by rhabdomyosarcoma (RMSA) in children.
  
  
  METHODS
  A retrospective case study was performed by searching a computer database for the patients with RMSA in whom F-18 FDG PET studies were performed pre- and posttreatment. The data of the PET studies from these patients were analyzed in conjunction with clinical treatment and other imaging studies to determine whether interval changes of F-18 FDG uptake by the RMSA reflect response of RMSA to treatment.
  
  
  RESULTS
  Four patients with RMSA who received both pretreatment and posttreatment F-18 FDG PET studies were identified from the database and included in this study. A dramatic decrease of F-18 FDG uptake by the tumor was evident in the patients who had a favorable response to the therapy and prolonged remission of the disease. In contrast, persistent abnormal FDG uptake in one patient was associated with early relapse of the RMSA.
  
  
  CONCLUSIONS
  F-18 FDG PET may be useful for monitoring therapeutic response by RMSA in children, which needs to be verified with a prospective study in a larger patient population.
authors.affiliation: The Carman & Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan 48201, USA. fpeng@pet.wayne.edu
authors.forename: Fangyu
authors.initials: F
authors.lastname: Peng
authors.forename: Galina
authors.initials: G
authors.lastname: Rabkin
authors.forename: Otto
authors.initials: O
authors.lastname: Muzik
mesh_terms: D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D007573:Jaw Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010255:Paranasal Sinus Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012074:Remission Induction; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D012888:Skull Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18